Overview

CD30biAb-AATC for CD30+ Malignancies

Status:
Not yet recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Collaborator:

Midwest Athletes Against Childhood Cancer

Treatments:

Antibodies
Antibodies, Bispecific